Loxo Oncology (LOXO) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts LOXO Hot Sheet
Join SI Premium – FREE
Note: EPS may not be comparable
Loxo Oncology (NASDAQ: LOXO) reported Q4 EPS of ($1.24), $0.09 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on Loxo Oncology (LOXO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Commerce.com, Inc. (CMRC) Tops Q3 EPS by 4c ; Offers Guidance
- LifeStance Health Group, Inc. (LFST) Tops Q3 EPS by 2c; Offers Guidance
- Unity Software Inc. (U) Tops Q3 EPS by 41c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
